Skip to Main Content

Paper Details

Prediction of life-threatening and disabling bleeding in patients with AML receiving intensive induction chemotherapy.
Blood Adv
6
2022
AML, DIC, acute myeloid leukemia, disseminated intravascular coagulation, patients, proliferative disease, prothrombin, visual impairment
Author NameAffiliation
Richard M StoneDana-Farber Cancer Institute, Harvard Medical School
Daniel J DeAngeloDana-Farber Cancer Institute, Harvard Medical School
Donna NeubergDana-Farber Cancer Institute
Marlise R LuskinDana-Farber Cancer Institute, Harvard Medical School
Robert Coleman LindsleyDana-Farber Cancer Institute, Harvard Medical School
  • 1 - 5

Datasets

Release 1.2